Latest Information Update: 21 Oct 1997
At a glance
- Originator Agouron Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Metalloprotease inhibitors; Peptide hydrolase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Oct 1997 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 20 Feb 1997 Preclinical development for Cancer in USA (Unknown route)